Company registration number 14059389 (England and Wales)
LEUKAEMIA CARE TRADING LIMITED
FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
PAGES FOR FILING WITH REGISTRAR
LEUKAEMIA CARE TRADING LIMITED
CONTENTS
Page
Balance sheet
1
Statement of changes in equity
2
Notes to the financial statements
3 - 5
LEUKAEMIA CARE TRADING LIMITED
BALANCE SHEET
AS AT
31 DECEMBER 2025
31 December 2025
- 1 -
2025
2024
Notes
£
£
£
£
Current assets
Debtors
4
99
35
Creditors: amounts falling due within one year
5
(206,299)
(205,714)
Net current liabilities
(206,200)
(205,679)
Capital and reserves
Called up share capital
100
100
Profit and loss reserves
(206,300)
(205,779)
Total equity
(206,200)
(205,679)

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the board of directors and authorised for issue on 24 June 2026 and are signed on its behalf by:
Mr Christopher R G Matthews-Maxwell (Chair)
Director
Company Registration No. 14059389
LEUKAEMIA CARE TRADING LIMITED
STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 DECEMBER 2025
- 2 -
Share capital
Profit and loss reserves
Total
£
£
£
Balance at 1 January 2024
100
(201,815)
(201,715)
Year ended 31 December 2024:
Loss and total comprehensive income for the year
-
(3,964)
(3,964)
Balance at 31 December 2024
100
(205,779)
(205,679)
Year ended 31 December 2025:
Loss and total comprehensive income for the year
-
(521)
(521)
Balance at 31 December 2025
100
(206,300)
(206,200)
LEUKAEMIA CARE TRADING LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
- 3 -
1
Accounting policies
Company information

Leukaemia Care Trading Limited is a private company limited by shares incorporated in England and Wales (number 14059389). The registered office is One Birch Court, Blackpole East, Worcester, WR3 8SG.

1.1
Basis of preparation

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Going concern

Atruet the time of approving the financial statements, the company is receiving ongoing support from Leukaemia Care Society. Thus the directors continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3
Revenue

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes.

1.4
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, and other short-term liquid investments with original maturities of three months or less.

1.5
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost, if necessary. Financial assets classified as receivable within one year are not amortised.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

LEUKAEMIA CARE TRADING LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
1
Accounting policies
(Continued)
- 4 -
Basic financial liabilities

Basic financial liabilities, including creditors, and loans from the parent charitable company, are initially recognised at transaction price. Financial liabilities classified as payable within one year are not amortised.

 

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers.

1.6
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

2
Judgements and key sources of estimation uncertainty

In the application of the company’s accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources.

 

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

3
Employees

The average monthly number of persons (excluding directors) employed by the company during the year was:

2025
2024
Number
Number
Total
0
0
4
Debtors
2025
2024
Amounts falling due within one year:
£
£
Other debtors
99
35
5
Creditors: amounts falling due within one year
2025
2024
£
£
Amounts owed to group undertakings
206,299
204,214
Other creditors
-
0
1,500
206,299
205,714
LEUKAEMIA CARE TRADING LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
- 5 -
6
Audit report information

As the income statement has been omitted from the filing copy of the financial statements, the following information in relation to the audit report on the statutory financial statements is provided in accordance with s444(5B) of the Companies Act 2006.

The auditor's report is unqualified and includes the following:

Opinion

In our opinion the financial statements:

Senior Statutory Auditor:
Elizabeth Needham ACA CTA (VAT)
Statutory Auditor:
Kendall Wadley LLP
Date of audit report:
24 June 2026
7
Parent company

The parent undertaking is Leukaemia Care, a charitable company, registered in England & Wales.

2025-12-312025-01-01falsefalsefalse24 June 2026CCH SoftwareCCH Accounts Production 2026.100No description of principal activityW DaviesMs E WilsonC R G Matthews-Maxwell140593892025-01-012025-12-31140593892025-12-31140593892024-12-3114059389core:CurrentFinancialInstrumentscore:WithinOneYear2025-12-3114059389core:CurrentFinancialInstrumentscore:WithinOneYear2024-12-3114059389core:CurrentFinancialInstruments2025-12-3114059389core:CurrentFinancialInstruments2024-12-3114059389core:ShareCapital2025-12-3114059389core:ShareCapital2024-12-3114059389core:RetainedEarningsAccumulatedLosses2025-12-3114059389core:RetainedEarningsAccumulatedLosses2024-12-3114059389core:ShareCapital2023-12-3114059389core:RetainedEarningsAccumulatedLosses2023-12-3114059389bus:Director32025-01-012025-12-3114059389core:RetainedEarningsAccumulatedLosses2024-01-012024-12-31140593892024-01-012024-12-3114059389core:RetainedEarningsAccumulatedLosses2025-01-012025-12-3114059389bus:PrivateLimitedCompanyLtd2025-01-012025-12-3114059389bus:SmallCompaniesRegimeForAccounts2025-01-012025-12-3114059389bus:FRS1022025-01-012025-12-3114059389bus:Audited2025-01-012025-12-3114059389bus:Director12025-01-012025-12-3114059389bus:Director22025-01-012025-12-3114059389bus:FullAccounts2025-01-012025-12-31xbrli:purexbrli:sharesiso4217:GBP